Drugmaker BTG bets on devices to help treat cancer

BTG is trialling matching cutting-edge cancer drugs to medical devices Credit: Dan Kitwood / Getty Images

FTSE 250-listed drug company BTG is to plough new investment into cutting-edge cancer therapies in a bid to shake up the fast growing global immuno-oncology (IO) drugs market.

BTG’s play in IO – a market worth $8bn (£6.2bn) a year today and projected to reach $50bn – is to develop medical devices that can deliver the immune system-boosting drugs directly to the cancer-affected part of the body using specially-designed needles, catheters or probes.

The British firm hopes this approach will prove more effective than the current method of ingesting the drug and altering the whole body’s immune system, which can lead to side effects, such…